A control group (CTR1) was not treated The time of ovulation was

A control group (CTR1) was not treated. The time of ovulation was estimated by transrectal LY2835219 ultrasound at 12-h intervals. Altrenogest treatment

significantly reduced pregnancy rate when start of treatment was before or at ovulation: 25% (5/20) compared to later start of treatment [85% (28/33)] and non-treated CTR1 [100% (23/23)]. Altrenogest treatment also reduced (p < 0.05) number of foetuses, from 14.6 +/- 2.6 in CTR1 to 12.5 +/- 2.5 when ALT started 11.5 days from ovulation and 10.7 +/- 2.9 when ALT started 00.5 days from ovulation. In a second experiment, sows with a weaning-to-oestrous interval (WOI) of 6, 7 or 814 days were given ALT [either 20 mg (ALT20; n = 49) or 10 mg (ALT10; n = 48)] at day 4 and day 6 after onset of oestrus or were not treated (CTR2; n = 49), and farrowing rate and litter size were evaluated. Weaning-to-oestrous interval did not affect farrowing rate or litter size. ALT did not affect farrowing rate (86% vs 90% in CTR2), but ALT20 tended to have a lower litter size compared with CTR2 (11.7 +/- 4.1 vs 13.3 +/- 3.1; p = 0.07) and ALT10 was intermediate (12.3 +/- 2.9). In conclusion, altrenogest supplementation too soon after ovulation reduces fertilization rate

and embryo survival rate and altrenogest supplementation at 46 days of pregnancy reduces litter size. As a consequence, altrenogest supplementation during early pregnancy may reduce both farrowing rate and litter size and cannot be applied at this stage in practice as a

remedy against low litter size.”
“Background and objective: To combine the diagnosis of OSA with titration of SNX-5422 positive airway pressure (PAP), current guidelines recommend that split-night polysomnography (PSG) be performed if an AHI of >= 40/h is recorded over 2 h. However, the diagnostic validity of partial-night PSG is uncertain. This study aimed to test the validity of partial-night PSG and to determine the optimum AHI cut-off points.

Methods: Patients who visited the sleep centre at a tertiary medical centre between January and December 2008, for symptoms related to sleep disorders (sleepiness, snoring, sleep disturbance), and who completed full-night PSG, were evaluated for this study. Full-night PSG data were processed to PD98059 concentration obtain partial-night PSG data, from which AHI were computed as a reference for diagnosing severe OSA. Full-night and partial-night PSG data obtained over different recording times (expressed as x-h PSG, where x = 1-6) were compared using receiver operating characteristic (ROC) curve analysis. The diagnostic validity of 2-h PSG with different AHI cut-off points (25/h to 45/h) was also calculated.

Results: Data from 198 PSG recordings was processed. For 2-h PSG, an AHI cut-off point of 30/h gave the highest accuracy of 90.9%. Comparing areas under the ROC curves (AUC), 2-h PSG (AUC = 0.97) was as good as 2.5-h PSG (AUC = 0.977, P = 0.057) and 3-h PSG (AUC = 0.978, P = 0.

Comments are closed.